Insmed initiates three Phase 3 trials of TPIP for pulmonary diseases
Insmed will feature its four-study Phase 3 PALM program for treprostinil palmitil inhalation powder at CHEST 2026. Three trials have begun; the fourth, PALM-IPF, is expected to start in the first half of 2027. The program aims to enroll more than 2,000 patients to evaluate once-daily treatment for pulmonary hypertensio